Second-generation taxane derivative with potential antineoplastic activity, binding to and stabilizing tubulin molecules, inhibiting cell division and cellular proliferation

Peripheral weak partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist, preventing from being absorbed and entering the central nervous system

Inhibitor of an enzyme responsible for the multidrug resistance phenotype in the yeast Saccharomyces cerevisiae.

Novel potent dual orexin 1/2 receptor (OX1/2R) antagonist for the treatment of insomnia

Novel sodium/calcium exchanger (NCX) inhibitor

Lipoglycopeptide Antibacterial, acting as a inhibitor of Cytochrome P450 2C19/2C9, and a inducer of Cytochrome P450 3A4/2D6

Selective p38alpha and p38beta kinase inhibitor

CB1 allosteric modulator

Negative allosteric modulator at the CB1 receptor

Novel mixed κ/μ receptor antagonist. having therapeutic potential for the treatment of depression and other stress-induced conditions

Collagen immunostain

Novel Potent, Well Tolerated, and Orally Active Protective Agent against Aminoglycoside-Induced Hearing Loss

Novel negative allosteric modulator (NAM) of mGlu4, being isomerized with blue-light/dark cycles with fast relaxation

Inhibitor of calmodulin action in calcium regulation

Antioxidant and free radical scavenger, attenuating edema formation, and subsequent tissue damage following cortical contusion

Metabolite of Cilostazol

Novel potent inhibitor of protein-protein interactions

Potent, selective, and orally active prostaglandin D2 receptor antagonist

Novel selective EP3 receptor agonist

EP(4)-selective antagonist

Novel agonist of the prostaglandin PGE2 receptor EP4

Novel selective EP2 receptor agonist, inducing relaxation of smooth muscle

Highly selective agonist of prostaglandin E2 receptor (EP2)

Potent, orally available dual CysLT1 and CysLT2 receptor antagonist

Lipid A analog, inducing Th1-type immune response in tumor eradication and restoring nitric oxide production by peritoneal macrophages

Protease inhibitor

Novel enhancer of Schwann cell differentiation for treatment of peripheral nerve disorder

Novel non-ATP-competitive inhibitor of BCR-ABL, overriding imatinib resistance

Potent analogue of oncrasin-1 with antitumor activity mediated by JNK activation and STAT3 inhibition

Non-ATP-competitive Bcr-Abl inhibitor, potently inhibiting imatinib-resistant Bcr-Abl mutants such as T315I